CliffBio
small molecule

COLISTIMETHATE SODIUM

COLISTIMETHATE SODIUM

Loss of exclusivity—loss of exclusivity
CompanyNexus Labs →See this company's full patent-cliff portfolio

Drug detail

Brand nameCOLISTIMETHATE SODIUM
Active ingredientCOLISTIMETHATE SODIUM
StrengthEQ 150MG BASE/VIAL
Dosage formINJECTABLE
RouteINJECTION
ModalitySmall molecule
FDA approvalMarch 2004
Marketing statusDISCN

More from Nexus Labs

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

COLISTIMETHATE SODIUM patent cliff — loss of exclusivity — | CliffBio